Alpha 2.0
Login Register
» Authors » Dominik Hlauschek

Dominik Hlauschek

Explore the profile of Dominik Hlauschek including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 173
Followers 0
Related Specialties
Oncology
General Surgery
Top 10 Co-Authors
Michael Gnant
Marija Balic
Christian Fesl
Richard Greil
Martin Filipits
Daniel Egle
Christian F Singer
Georg Pfeiler
Florian Fitzal
Lidija Solkner
Published In
Breast Cancer Res Treat
J Clin Oncol
Clin Cancer Res
JAMA Oncol
Nat Cancer
Affiliations
Soon will be listed here.
Recent Articles
11.
Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12
Beltran-Bless A, Clemons M, Fesl C, Greil R, Pond G, Balic M, et al.
Eur J Cancer . 2023 Jan; 180:108-116. PMID: 36592505
Background: The widespread adoption of adjuvant bisphosphonate therapy for postmenopausal early breast cancer (EBC) patients was based on results of the Early Breast Cancer Trialist Group (EBCTCG) meta-analysis. Despite multiple...
12.
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer...
Mayer E, Fesl C, Hlauschek D, Garcia-Estevez L, Burstein H, Zdenkowski N, et al.
J Clin Oncol . 2022 Jan; 40(5):449-458. PMID: 34995105
Purpose: The PALLAS study investigated whether the addition of palbociclib, an oral CDK4/6 inhibitor, to adjuvant endocrine therapy (ET) improves invasive disease-free survival (iDFS) in early hormone receptor-positive (HR+), human...
13.
The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8
Filipits M, Rudas M, Kainz V, Singer C, Fitzal F, Bago-Horvath Z, et al.
Clin Cancer Res . 2021 Aug; 27(21):5931-5938. PMID: 34380638
Purpose: To validate the clinical performance of the OncoMasTR Risk Score in the biomarker cohort of Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 8. Experimental Design: We evaluated...
14.
Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2...
Saura C, Hlauschek D, Oliveira M, Zardavas D, Jallitsch-Halper A, de la Pena L, et al.
Lancet Oncol . 2019 Aug; 20(9):1226-1238. PMID: 31402321
Background: Endocrine therapy-based neoadjuvant treatment for luminal breast cancer allows efficient testing of new combinations before surgery. The activation of the phosphatidylinositol-3-kinase (PI3K) pathway is a known mechanism of resistance...
15.
Prediction of Distant Recurrence Using EndoPredict Among Women with ER, HER2 Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only
Filipits M, Dubsky P, Rudas M, Greil R, Balic M, Bago-Horvath Z, et al.
Clin Cancer Res . 2019 May; 25(13):3865-3872. PMID: 31064782
Purpose: Prognostic molecular assays may aid in treatment decisions for women with estrogen receptor (ER)-positive, HER2-negative breast cancer. The prognostic value of a 12-gene expression assay (EndoPredict) was reevaluated in...
16.
Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
Sestak I, Martin M, Dubsky P, Kronenwett R, Rojo F, Cuzick J, et al.
Breast Cancer Res Treat . 2019 May; 176(2):377-386. PMID: 31041683
Purpose: EndoPredict (EPclin) is a prognostic test validated to inform decisions on adjuvant chemotherapy to endocrine therapy alone for patients with oestrogen receptor-positive, HER2-negative breast cancer. Here, we determine the...